Synonyms: CVT-303 | Ranexa® | RS-43285 | RS-43285-003
ranolazine is an approved drug (FDA (2006), EMA (2008))
Compound class:
Synthetic organic
Comment: The mechanism of action of ranolazine is largely unknown, but may have some antianginal effects by inhibition of the late sodium current in cardiac cells.
View more information in the IUPHAR Pharmacology Education Project: ranolazine |
|
Classification | |
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2006), EMA (2008)) |
IUPAC Name |
N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}ethanimidic acid |
International Nonproprietary Names | |
INN number | INN |
5946 | ranolazine |
Synonyms |
CVT-303 | Ranexa® | RS-43285 | RS-43285-003 |
Database Links | |
CAS Registry No. | 95635-55-5 |
ChEMBL Ligand | CHEMBL1404 |
DrugBank Ligand | DB00243 |
DrugCentral Ligand | 2359 |
GtoPdb PubChem SID | 178103865 |
PubChem CID | 56959 |
Search Google for chemical match using the InChIKey | XKLMZUWKNUAPSZ-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | XKLMZUWKNUAPSZ |
Search PubMed clinical trials | ranolazine |
Search PubMed titles | ranolazine |
Search PubMed titles/abstracts | ranolazine |
UniChem Compound Search for chemical match using the InChIKey | XKLMZUWKNUAPSZ-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | XKLMZUWKNUAPSZ-UHFFFAOYSA-N |
Wikipedia | Ranolazine |